CHMP recommends Prezista in treatment-naïve HIV
This article was originally published in Scrip
The EU's CHMP has recommended a label extension for Janssen-Cilag'sHIV protease inhibitor Prezista (darunavir) to include its use as part of an anti-HIV combination regimen, co-administered with low-dose ritonavir, in treatment-naïve HIV-1 infected adults. This indication comes with a new strength of 400mg film-coated tablet.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.